Endometrial Cancer Clinical Trials in Stavanger
2 recruitingStavanger, Norway
Showing 1–2 of 2 trials
Recruiting
Phase 3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
AstraZeneca600 enrolled249 locationsNCT06989112
Recruiting
Phase 4
Biomarker Guided Treatment in Gynaecological Cancer
Endometrial Cancer
Haukeland University Hospital1,300 enrolled9 locationsNCT02543710